The future costs, risks and rewards of drug development: The economics of pharmacogenomics

PharmacoEconomics

Volumn 27, Issue 5, 2009, Pages 355-363

  Cook, Joseph ^a   Hunter, Graeme ^a   Vernon, John A ^b,c  

^a NERA ECONOMIC CONSULTING   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; ECONOMIC ASPECT; GENETIC MARKER; GENOME; INVESTMENT; NOTE; PATIENT SELECTION; PHARMACOGENOMICS; PRIORITY JOURNAL; PROFIT; RISK;

COSTS AND COST ANALYSIS; DRUG DISCOVERY; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; FORECASTING; HUMANS; PHARMACOGENETICS; RESEARCH; REWARD; RISK;

EID: 67749120865     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-200927050-00001     Document Type: Note

References (26)

1. Human Genome Project information [online]. Available from URL: http://www.ornl.gov/sci/techresources/Human-Genome/medicine/pharma.shtml [Accessed 2009 Apr 28]
2. McWilliam A, Lutter R, Nardinelli C. Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. Personal Med 2008 May; 5 (3): 281
3. Pollack A. Patient's DNA may be signal to tailor medication. New York Times [online]. Available from URL: http://www.nytimes.com/2008/12/30/business/ 30gene.html [Accessed 2009 Apr 28]
4. Genentech USA, Inc. What is herceptin? [online]. Available from URL: http://www.herceptin.com/adjuvant/what-is/ index.jsp [Accessed 2009 Apr 28]
5. Press M, Seelig SA. Lessons learned from the development of a diagnostic to predict response to herceptin: targeted medicine: from concept to clinic. Thomson Financial Street Events, 2004 [online]. Available from URL: http://www. targetedmed.com/flash/lib/pdf/Targeted%20Medicine%20 Report.pdf pp. 9-10 [Accessed 2009 Apr 28]
6. Personalized medicine - today! Clinical Ligand Assay Society; 32nd International Meeting; 2006 May 22; Louisville (KY). Slide 23 [online]. Available from URL: http://www.fda. gov/cder/genomics/presentations/CLAS.pdf [Accessed 2009 Apr 28]
7. DiMasi J, Hansen R, Grabowski G. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-85
8. Vernon JA, Johnson S, Hughen WK, et al. Economic and development considerations for pharmacogenomics technology. Pharmacoeconomics 2006; 24 (5): 335-43
9. Haley S. Personalized medicine not a threat to blockbuster model: Lilly President Lechleiter. Pink Sheet Daily 2007 Nov 30; 007
10. Spears B, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001 May; 7 (5): 201-4
11. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001 Nov 14; 286 (18): 2270-9
12. Better, faster, smaller: personalized medicine could bring R&D savings. Pink Sheet 2008 Mar 3; 70 (9): 24
13. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008 Feb 7; 358 (6): 637-9
14. Berenson A. Pfizer ends studies on drug for heart disease. New York Times 2006 Dec 3 [online]. Available from URL: http://www.nytimes.com/2006/12/03/ health/03pfizer. html [Accessed 2009 Apr 28]
15. Editorial: looking forward, looking back. Nature Biotechnology 2008 May (corrected 2008 June 13); 26 (5): 475 [online]. Available from URL: http://www.nature.com/ nbt/journal/v26/n5/pdf/nbt0508-475.pdf [Accessed 2009 Apr 28]
16. GSK, Merck KGaA agree to end joint Vilazodone development. Apr 17, 2003 [online]. Available from URL: http:// www.lexdon.com/article/gsk-merck-kgaa- agree-to/125249. html [Accessed 2009 Apr 27]
17. Clinical Data. Clinical Data delivers Vilazodone milestone payment to Merck KGaA. Dec10, 2007 [online]. Available from URL: http://investor.clda.com/ releasedetail.cfm? ReleaseID=280467 [Accessed 2009 Apr 27]
18. BioPharma Today [online]. Available from URL: http:// www.biopharmatoday.com/2008/09/arca-files-nda.html# more [Accessed 2008 Sep 30]
19. Winslow R. Gene analysis boosts sidelined heart drug. Wall Street J 2008 Sep 23; D2 [online]. Available from URL: http://online.wsj.com/article/ SB122212399407465005.html [Accessed 2009 Apr 28]
20. DiMasi JA, Grabowski HG. Managerial and decision economics. Vol. 28. West Sussex: John Wiley & Sons Ltd, 2007: 469-79
21. Cockburn IM. The changing structure of the pharmaceutical industry [online]. Available from URL: http://content.health-affairs.org/cgi/reprint/23/ 1/10.pdf [Accessed 2009 Apr 28]
22. Vernon JA. Examining the link between price regulation and pharmaceutical R&D investment. Health Econ 2005; 14 (1): 1-16
23. Giaccotto C, Santerre R, Vernon JA. Pricing and R&D investment behavior in the pharmaceutical industry. J Law Econ 2005; 48: 195-207
24. Lichtenberg FR. Sourcesof U.S. longevity increase, 1960-1997. Cambridge (MA): NBER working paper 8755, 2002 Feb
25. Cutler DM, McClellan M. Is technological change in medicine worth it? Health Affairs 2001 Sep/Oct; 20 (5): 11-29
26. Murphy KM, Topel RH. Measuring the gains from medical research: an economic approach. In: Murphy KM, Topel RH, editors. Chicago (IL): University of Chicago Press, 2003